


## PHARMACEUTICAL 2023

## Acer Therapeutics Inc. Rank 407 of 446







## PHARMACEUTICAL 2023

## Acer Therapeutics Inc. Rank 407 of 446



The relative strengths and weaknesses of Acer Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acer Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 103% points. The greatest weakness of Acer Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 195% points.

The company's Economic Capital Ratio, given in the ranking table, is -275%, being 318% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	3,517
Cost of Goods Sold	0
Intangible Assets	7,647
Liabilities, Current	18,952
Liabilities, Non-Current	146
Other Assets	246
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	9,288
Other Net Income	-1,623
Other Revenues	0
Property and Equipment	215
Research and Development	11,925
Selling, General and Administrative Expense	12,689

Output Variable	Value in 1000 USD
Assets	11,624
Liabilities	28,385
Expenses	24,614
Revenues	0
Stockholders Equity	-16,761
Net Income	-26,237
Comprehensive Net Income	-26,237
Economic Capital Ratio	-275%

